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neuroleptic/serotonin syndrome, impulse control disorder, somnolence, sleep 
attacks, hallucinations, psychoses) and for all AEs combined. Index dates were 
assigned as first AE diagnosis for cases and first anti-PD prescription claim for 
controls. Patients were enrolled pre-index for ≥6 months and post-index for ≥12 
months. All-cause costs were aggregated over 12 months post-index. Costs  
(2012 $) were adjusted using GLM models with covariates for demographics and 
pre-index comorbidities. RESULTS: A total of 71,883 patients met the inclusion 
criteria, 45,719 with ≥1 AE (mean[SD] age: 74.9[11.0] years, 55% male) and 26,164 
with no AEs (mean[SD] age: 75.0[10.9] years, 59% male). Among patients with ≥1 
AE, mean total all-cause costs per patient were substantially higher as compared 
with controls ($23,568 vs. $13,633; p<0.001), with the difference driven roughly 
equally by incremental inpatient and outpatient costs of $4,398 and $5,031, 
respectively (both p<0.001). For all AEs individually, patients experiencing the AE 
had substantially higher mean all-cause costs, with the largest differences for 
orthostatic hypotension ($30,551 vs. $17,635), hallucinations ($30,822 vs. $17,843), 
and nausea ($32,865 vs. $16,456) (all p<0.001). CONCLUSIONS: PD patients 
experiencing AEs incur substantially higher costs as compared with patients 
without AEs. These data may be useful in evaluating the cost-effectiveness of 
new PD therapies with more favorable AE profiles.  
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OBJECTIVES: The current study is a longitudinal analysis of costs in dementia 
from a societal perspective. The data were collected as part of the AgeCoDe 
study. The aim of this study is to analyse excess costs of dementia over time 
while taking into account the initial degree of severity and to investigate 
potential predictors of costs over time. METHODS: Health care resource use and 
costs were assessed retrospectively using a questionnaire in four waves at 6-
month intervals in a sample of dementia patients (N=175) and a non-demented 
control sample (N=173) matched for age and gender. Sociodemographic data, 
dementia severity and comorbidity at baseline, cognitive impairment and 
impairment in activities of daily living (ADL) were also recorded. Statistical 
analyses were performed by means of the χ2 test or Fisher’s exact test, two-tailed 
t-tests and linear mixed regression models with random intercepts for 
individuals. We used bootstrapped standard errors (based on 4000 replications) 
in regression analyses to account for the skewness of the cost data. RESULTS: 
For patients with mild dementia, costs increased by approximately €900 (US-
$1250) per six months, while they decreased by €2700 (US-$3750) in patients with 
severe dementia. ADL impairment significantly predicted total costs in dementia 
patients. Higher age was associated with higher formal care costs, but lower 
informal care costs. CONCLUSIONS: In patients with mild dementia, costs rose 
over time, while they decrease in severely demented patients. Transition into a 
nursing home is likely in severely demented patients, which may reduce total 
costs from a societal perspective, owing to the fact that a high amount of 
informal care required by severely demented patients prior to transition into a 
nursing home may cause higher costs than inpatient nursing care.  
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OBJECTIVES: Patients with multiple sclerosis (MS) who have relapses are treated 
with corticosteroids and sometimes admitted to the hospital. The objective of 
this study is to examine changes in corticosteroid utilization, MS-related 
inpatient hospitalization, and related costs in MS patients before and after 
initiating natalizumab treatment in a real-world setting. METHODS: A 
retrospective administrative claims analysis was conducted using a large US 
commercial and Medicare supplemental database. The study population 
included adult patients diagnosed with MS who initiated natalizumab treatment 
between January 1, 2007, and December 31, 2010 (index), had not received any 
MS disease-modifying therapy for 12 months prior to index, and had ≥24 months 
of continuous data (12 months before and after index). Patient characteristics at 
index and corticosteroid use, MS-related inpatient hospitalizations, and related 
costs 12 months before (pretreatment) and 12 months after (posttreatment) 
natalizumab treatment initiation were analyzed and described using paired 
statistical tests. RESULTS: Data were from 535 patients: 70.1% female, mean age 
45.8 (standard deviation 11.2) years. Compared with the previous 12 months, the 
proportions of patients with oral and IV corticosteroid use significantly 
decreased by 10.3% (28.6% pretreatment vs 18.3% posttreatment; P<0.001) and 
16.7% (34.8% pretreatment vs. 18.1% posttreatment; P<0.001), respectively, after 
12 months from natalizumab initiation. Mean expenditure per patient of oral and 
IV corticosteroid prescriptions decreased by 57.1% (P=0.002) and 54.7% (P=0.007), 
respectively. A significant reduction was observed in the proportion of patients 
with MS-related inpatient hospitalizations (7.3% pretreatment vs. 3.0% 
posttreatment; P=0.001), as well as in MS-related inpatient hospital expenditures 
among patients with an inpatient admission (median cost per patient: $12,078 
pretreatment vs $9,289 posttreatment; P=0.001). CONCLUSIONS: Indicators of MS 
relapses, MS-related inpatient hospitalizations and corticosteroid use, were 
significantly reduced in MS patients 12 months after initiating natalizumab 
treatment in a real-world setting both in terms of costs and health resource 
utilization.  
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OBJECTIVES: Hemophilia is a genetic disease in which there is a deficiency in the 
level of activity of the coagulation factors. Hemophilia A (factor VIII deficiency) 
has a prevalence of 3.96 per 100,000 in Colombia (96.7% male); Severe hemophilia 
is defined as a blood clotting factor level ≤1%. This analysis is aimed to estimate 
the cost-effectiveness of prophylactic treatment of severe hemophilia A, 
compared to demand treatment in Colombia. METHODS: A decision tree model 
was developed using a time horizon of life expectancy. A societal perspective 
was adopted; annual discount rate of 3% was applied to costs and effectiveness 
measures. Prophylactic treatment with recombinant factor VIII (25 UI/kg 3 times 
per week) was compared to on demand treatment (50 UI/kg TID for 7 days for 
each bleeding episode). A cohort of 1,000 patients (0-14 years) with an average 
weight of 40kg and inhibitors present was simulated. Effectiveness and 
probabilities of adverse events were taken from the literature. Costs (direct and 
indirect) were taken from local tariff manuals (SOAT and SISMED). Effectiveness 
measures were number of cases avoided of bleeding and joint damage. All data 
were validated with a clinical expert. Univariate sensitivity analysis was done. 
Costs are presented in 2012 US$. RESULTS: Over the time horizon evaluated, 
prophylactic treatment avoids 823 cases of bleeding and 292 of joint damage. 
Total expected costs with prophylactic treatment were US$2.6M compared to on 
demand treatment US$1.7M. The incremental cost effectiveness ratio (ICER) for 
prophylactic treatment was US$1,079/avoid bleed, US$3,042/avoided joint 
damage. Sensitivity analysis showed the robustness of the model. 
CONCLUSIONS: From the social perspective, prophylactic treatment of severe 
hemophilia A, with recombinant factor VIII would be a highly cost-effectiveness 
intervention with strong health benefits in number of cases of bleeding and joint 
damage avoided (cost-effectiveness threshold: 1 Colombian GDP per capita = 
US$7,235).  
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OBJECTIVES: Few studies regarding the head-to-head cost-effectiveness analysis 
of medications treating for Alzheimer’s Disease have been conducted in Asia. 
The goal of this study is to perform a comparative assessment of donepezil and 
rivastigimine on the costs and efficacy of mild to moderate AD patients. 
METHODS: A four-state Markov model was built to simulate the disease 
progression of the mild to moderate AD patients’ life span (from sixty five years 
of age to death). Transition probabilities between states and the cost of medical 
treatments at different stages derived from the local data in Taiwan. Analyses 
were run to evaluate outcomes for patients with mild AD from societal 
perspective. While all cost outcome have been discounted at 3% per annum. 
RESULTS: The result of the Markov cohort simulation shows that for the life 
expectancy in the long-term, rivastigmine treatment is the dominant strategy as 
it is more effective and economical than the alternatives. Specifically, treating 
patients with rivastigmine, compared with no treatment, yielded a 0.34 quality-
adjusted life years (QALYs) increase per patient over the life time. Furthermore, 
the average cost savings per patient favored rivastigmine by resulting in 
US$10,503 from the societal perspective (2012 USD). For the donepezil versus 
rivastigmine base-case comparison, patients on donepezil gained 0.64 QALYs. 
Cost savings for the donepezil group were US$50,312 from the societal 
perspective. CONCLUSIONS: It is concluded that donepezil and rivastigmine are 
the two medical treatments that might be a cost saving strategy for mild or 
moderate AD patients in Taiwan from the societal perspective.  
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OBJECTIVES: Hemophilia is a recessive genetic disease that does not allow 
adequate blood clotting; this is characterized by a defect in coagulation factors, 
needed for this function. Hemophilia B (factor IX deficiency) has a prevalence of 
0.81 per 100,000 in Colombia (96% male). Severe hemophilia is defined as a blood 
clotting factor level ≤1%. This analysis is aimed to estimate the cost-
effectiveness of prophylactic treatment of severe hemophilia B, compared to on 
demand treatment in Colombia. METHODS: A decision tree model was 
developed using a time horizon of life expectancy. A societal perspective was 
adopted, and an annual discount rate of 3% was applied to costs and 
effectiveness measures. Prophylactic treatment with recombinant factor IX (25 
IU/kg 2 times per week) was compared to on demand treatment (50 UI/kg TID for 
8.5 days for each bleeding episode). A cohort of 1000 patients (age 15 - 62), with 
an average weight of 60kg was simulated: estimates of effectiveness and 
probabilities of adverse events were taken from a literature. Costs (direct and 
indirect) were taken from local tariff manuals (SOAT and SISMED). Costs are 
presented in 2012 US$. Effectiveness measures were number of cases avoided of 
bleeding and joint damage. All data were validated with a clinical expert. 
